Iain Dukes, D.Phil.

Chairman of the Board

Dr. Dukes joined the Iovance Board of Directors and was appointed Chairman of the Board in August 2016. Dr. Dukes is a Venture Partner at OrbiMed Advisors. He previously served as Senior Vice President and Head of Business Development and Licensing for Merck Research Laboratories. Prior to joining Merck, Dr. Dukes was Vice President of External Research and Development at Amgen. He has also served as President and Chief Executive Officer, as well as a member of the Board of Directors of Essentialis Therapeutics, a clinical stage biotechnology company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases. Previously, Dr. Dukes was Vice President of Scientific and Technology Licensing at GlaxoSmithKline, and he held various positions at Glaxo Wellcome, including Head of Exploratory Development for Metabolic and Urogenital Diseases and Head of Ion Channel Drug Discovery Group. Dr. Dukes serves on the Board of Directors of Themis Biosciences, Ikena Oncology, KaNDy Therapeutics (previously as Chairman), NeRRe Therapeutics, ReViral Limited and ENYO Therapeutics. Dr. Dukes co-founded and is the former Chief Executive Officer of Theseus Pharmaceuticals. He also co-founded and serves on the Board of Directors of Kartos Therapeutics, and co-founded Telios Pharma, where he serves as President. He holds an M.J. and D.Phil. from the University of Oxford, an M.S. in Cardiovascular Studies from the University of Leeds, and a B.S. in Pharmacology from the University of Bath.

Committees

  • Nominating and Corporate Governance Committee
    Chair

Athena Countouriotis, M.D.

Director

Dr. Countouriotis is the co-founder and Chief Executive Officer of Avenzo Therapeutics, a private biotechnology company focused on oncology. Previously she was the President and Chief Executive Officer and a board member of Turning Point Therapeutics from 2018 until it was acquired by Bristol-Myers Squibb in August 2022. Dr. Countouriotis has also served as the Chief Medical Officer for multiple public biotechnology companies, including Adverum Biotechnologies, Halozyme Therapeutics and Ambit Biosciences. Earlier in her career, Dr. Countouriotis led development of products for Pfizer and Bristol-Myers Squibb, including Sutent®, Mylotarg®, Bosulif® and Sprycel®. She also serves on the board of directors at Passage Bio and privately held biotechnology companies Capstan Therapeutics, Leal Therapeutics and Recludix Therapeutics. Dr. Countouriotis holds an undergraduate degree from the University of California, Los Angeles and an M.D. from the Tufts University School of Medicine. She received training at the University of California, Los Angeles and at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology-Oncology Program.

  • Nominating and Corporate Governance Committee
    Member
  • Compensation Committee
    Member

Ryan Maynard

Director

Mr. Maynard currently serves as Chief Financial Officer of Cara Therapeutics, Inc., a publicly-traded commercial-stage biopharmaceutical company. He previously served as the Chief Financial Officer of Paulus Holdings Ltd. d/b/a LetsGetChecked. Prior to LetsGetChecked, he was the Chief Financial Officer of Blade Therapeutics, Inc., a privately held biotechnology company. Mr. Maynard has served in various executive roles at Rigel Pharmaceuticals, Inc., a public commercial-stage drug development company, including 10 years as Chief Financial Officer. He also served as Corporate Controller and Director of Finance and Accounting for Personify, Inc., an e-commerce software company, and Controller of General Magic, Inc. Mr. Maynard has held various positions at Siliconix, Inc., including Senior Finance Manager. He previously worked at Ernst and Young LLP. He holds a B.S. in Commerce–Accounting from Santa Clara University.

Committees

  • Audit Committee
    Chair

Merrill A. McPeak

Director

General (Ret.) McPeak has extensive leadership experience in the military and as a member of public and private company boards of directors. He joined the Iovance Board of Directors in July 2011, and served as the interim Chief Executive Officer of Iovance from January 2013 until July 2013. General McPeak is currently the President of McPeak and Associates, a consulting firm that he founded in 1995. General McPeak previously served as a director of several public companies, including Tektronix, Inc., Trans World Airlines, Inc., and ECC International Corp., where he was for many years the Chairman of the Board. General McPeak has served as Director of Research Solutions, Inc., Aerojet Rocketdyne, Lilis Energy, Valence Surface Technologies and Navex Global. He was Chairman of the Board of Coast Plating, Inc., a privately held turnkey provider of metal processing and metal finishing services, from January 2009 until the company was acquired by Trive Capital and renamed Valence Surface Technologies. General McPeak helped found and served as Chairman of the Board of EthicsPoint, Inc., a provider of risk management and compliance software as a service that was acquired in 2012 and restyled Navex Global.

From 1990 until his retirement from active military service in late 1994, General McPeak was Chief of Staff of the United States Air Force. As a member of the Joint Chiefs of Staff, General McPeak was a military advisor to the Secretary of Defense and the President of the United States. He received a B.A. in Economics from San Diego State College and an M.S. in International Relations from George Washington University and is a member of the Council on Foreign Relations. From July 2010 to December 2017, General McPeak was Chairman of the American Battlefield Monuments Commission.

Committees

  • Nominating and Corporate Governance Committee
    Member
  • Audit Committee
    Member
  • Compensation Committee
    Member

Wayne Rothbaum

Director

Wayne Rothbaum is president of Quogue Capital, a single-family office private equity fund focused on investing and supporting small to midcap life sciences companies. Mr. Rothbaum began his career at The Carson Group, a strategic consulting firm, where he managed its life sciences practice and boutique investment bank Evolution Capital. Following The Carson Group’s sale to Thomson Reuters in 2001, Mr. Rothbaum founded Quogue Capital, through which he has founded and/or invested in numerous private and public life sciences companies.

In 2012, Mr. Rothbaum co-founded and was the Executive Chairman of Acerta Pharma, a private life sciences company he later sold to AstraZeneca. Acerta’s lead drug, Calquence® (acalabrutinib) was approved by the FDA for mantle cell lymphoma in 2017 and chronic lymphocytic leukemia in 2020. In 2016, Mr. Rothbaum also co-founded Kartos Therapeutics following the in-license of an investigational MDM2 inhibitor from Amgen. More recently, in 2019, he co-founded Telios Pharma after licensing a novel targeted therapy from Merck KGaA to treat selected blood cancers and ophthalmology diseases. Additionally, Mr. Rothbaum has taken a leadership role in transforming Iovance, restructuring and reorganizing its Board of Directors, senior management and overall clinical operations and strategy. Currently, Mr. Rothbaum is a board member and its largest shareholder.

Mr. Rothbaum graduated Phi Beta Kappa from Binghamton University in 1990 with a dual major in political science and psychology and received his MA in international economics from The George Washington University. He is listed as an inventor on many scientific patents and is published in numerous medical journals, including The New England Journal of Medicine, The Lancet and the Journal of Clinical Oncology.

Committees

  • Compensation Committee
    Member

Michael Weiser, M.D., Ph.D.

Director

Dr. Weiser is the Founder and a Principal of Actin Biomed LLC, a healthcare investment firm focused on the discovery and development of novel treatments for unmet medical needs. Prior to joining Actin Biomed, Dr. Weiser was the Director of Research at Paramount BioCapital, Inc., a pharmaceutical development and healthcare investment firm. Dr. Weiser previously served as the Chairman of the Board of Directors of Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company that was acquired by H. Lundbeck A/S in 2014. He also served on the Board of Directors of Emisphere Technologies, Inc., a pharmaceutical and drug delivery company, and Ziopharm Oncology, Inc., a publicly traded biopharmaceutical company focused on immunotherapies in oncology. Dr. Weiser holds a B.A. in Psychology from the University of Vermont, received an M.D. from New York University School of Medicine, and completed a Ph.D. in Molecular Neurobiology at Cornell University Medical College.

Commitees

  • Compensation Committee
    Chair
  • Audit Committee
    Member
  • Nominating and Corporate Governance Committee
    Member

Wendy L. Yarno

Director

Ms. Yarno retired in September 2008 from Merck & Co., Inc., following a 26-year career there in commercial and human resource positions of increasing seniority, most recently Executive Vice President and Chief Marketing Officer before she retired. In that role, Ms. Yarno led an organization charged with global commercialization strategy and all aspects of supporting pre-and post-launch commercialization of pharmaceuticals in more than 20 therapeutic areas. Ms. Yarno currently serves on the board of directors of publicly traded life sciences companies Ideaya Bio, Inc., Tarsus Pharmaceuticals, Inc., and Inovio Pharmaceuticals, Inc. She formerly served on the boards of St. Jude Medical, Inc., MyoKardia, Inc., Medivation, Inc., Global Blood Therapeutics, Inc., Aratana Therapeutics, Inc., Alder Biopharmaceuticals, Inc. and Durata Therapeutics, Inc., prior to their acquisitions. Ms. Yarno received a B.S. in Business Administration from Portland State University and an M.B.A. from Temple University.

Committee

  • Audit Committee
    Member
See Our Research Partners & Collaborators